Related Experiment Video
Updated: Dec 21, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Current status of heart failure: global and Korea
1Cardiovascular Center, Division of Cardiology, Seoul National University Bundang Hospital, Seongnam, Korea.
Insights
Heart failure (HF) is a growing concern in aging populations. This review examines HF epidemiology, treatments, and emerging therapies worldwide, highlighting challenges in managing HF with preserved ejection fraction.
Area of Science:
- Cardiology
- Public Health
- Geriatrics
Background:
- Heart failure (HF) is a critical condition with significant morbidity and mortality.
- Increasing prevalence of HF is linked to aging populations and risk factors.
- Current treatments improve outcomes but leave residual risk, especially for HF with preserved ejection fraction.
Purpose of the Study:
- To review the epidemiology and temporal trends of heart failure.
- To summarize current medical, device, and transplantation therapies for HF.
- To explore emerging treatments and challenges in HF management, particularly HFpEF.
Main Methods:
- Literature review of epidemiological data.
- Analysis of current treatment modalities for heart failure.
- Discussion of global and Korean trends in HF therapy.
Main Results:
- HF prevalence is rising globally, particularly in aging societies.
- Medical and device therapies have advanced but have limitations.
- Effective treatments for HF with preserved ejection fraction (HFpEF) remain a challenge.
Conclusions:
- HF poses a significant public health challenge, especially for the elderly.
- Further research is needed for HFpEF and personalized treatment strategies.
- A comprehensive approach integrating existing and novel therapies is crucial for improving HF outcomes worldwide.
Abstract:
Heart failure (HF) is a condition in which the heart is unable to pump enough blood to meet the body's needs for blood and oxygen. Thus, HF is a grave disease with high morbidity and mortality. Because the prevalence of and exposure to the risk factors for HF increase with age, the prevalence of HF has been increasing in an aging society, including Korea. The vast advancement of medical and device therapy has improved the outcomes of HF, but significant residual risk still exists, and the benefit is confined to patients with reduced ejection fraction. Finding effective treatment for HF with preserved ejection fraction and identification of groups who benefit from drug and device therapy remain challenging. In this review, we illustrate the epidemiology, temporal trends, and current status of medical and device therapy, including heart transplantation, as well as emerging treatments for HF in Korea and worldwide.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VII: Nursing Interventions
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology